Indivior shares surge following robust Q1 revenue and positive outlook

Published 24/04/2025, 09:10
© Reuters.

Investing.com -- Shares of Indivior, a company known for its anti-opioid treatments, rose as much as 6.3% to 738.5p.

This surge came after the company reported its Q1 total net revenue of $266 million, surpassing the consensus estimate of $243 million, as per the analysis by Jefferies.

In addition to the strong revenue report, Indivior also reiterated its financial guidance for the fiscal year 2025.

The company remains confident in its financial outlook, which is a positive signal to investors and the market.

Furthermore, the company expressed optimism about the performance of its key product, SUBLOCADE. Indivior anticipates that SUBLOCADE will see growth in the second half of the year.

This expectation further boosted investor confidence and contributed to the rise in the company’s share price.

Indivior’s recent performance and positive outlook for its key product suggest a promising future for the company, reflected in the stock market’s positive response.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.